Incentives for global public health : patent law and access to essential medicines
著者
書誌事項
Incentives for global public health : patent law and access to essential medicines
(Connecting international law with public law / series editors, Kim Rubenstein, Thomas Pogge)
Cambridge University Press, 2010
- : hardback
大学図書館所蔵 全9件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Bibliography: p. 425-485
Includes index
内容説明・目次
内容説明
This portrait of the global debate over patent law and access to essential medicines focuses on public health concerns about HIV/AIDS, malaria, tuberculosis, the SARS virus, influenza, and diseases of poverty. The essays explore the diplomatic negotiations and disputes in key international fora, such as the World Trade Organization, the World Health Organization and the World Intellectual Property Organization. Drawing upon international trade law, innovation policy, intellectual property law, health law, human rights and philosophy, the authors seek to canvass policy solutions which encourage and reward worthwhile pharmaceutical innovation while ensuring affordable access to advanced medicines. A number of creative policy options are critically assessed, including the development of a Health Impact Fund, prizes for medical innovation, the use of patent pools, open-source drug development and forms of 'creative capitalism'.
目次
- Introduction: access to essential medicines: public health and international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein
- Part I. International Trade: 1. TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis Rochelle Cooper Dreyfuss
- 2. The TRIPS waiver as a recognition of public health concerns in the WTO Andrew Mitchell and Tania Voon
- 3. Public law challenges to the regulation of pharmaceutical patents in the US Bilateral Free Trade Agreements Hitoshi Nasu
- 4. Global health and development: patents and public interest Elizabeth Siew Kuan Ng
- Part II. Innovation: 5. The Health Impact Fund: boosting innovation without obstructing free access Thomas Pogge
- 6. The Health Impact Fund: a critique Kathleen Liddell
- 7. A prize system as a partial solution to the health crisis in the developing world William W. Fisher and Talha Syed
- 8. Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation Thomas Faunce
- Part III. Intellectual Property: 9. Opening the dam: patent pools, innovation, and access to essential medicines Dianne Nicol and Jane Nielsen
- 10. Open source drug discovery: a revolutionary paradigm or a utopian model? Krishna Ravi Srinivas
- 11. Accessing and benefit sharing avian influenza viruses through the World Health Organization: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking
- 12. The Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer
- Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and access to essential medicines Noah Benjamin Novogrodsky
- 14. Securing health through rights Katharine Young
- 15. The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India Rajshree Chandra
- 16. Tipping point: Thai compulsory licenses redefine essential medicines debate Jonathan Burton-MacLeod.
「Nielsen BookData」 より